{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T05:30:15Z","timestamp":1736227815913,"version":"3.32.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Tianjin Science and Technology Commission key project","award":["21JCZDJC00980","21JCZDJC00980","21JCZDJC00980"],"award-info":[{"award-number":["21JCZDJC00980","21JCZDJC00980","21JCZDJC00980"]}]},{"name":"Special Research Fund for Clinical Studies of Innovative Drugs after Market Launch","award":["WKZX2024CX102217","WKZX2024CX102217","WKZX2024CX102217"],"award-info":[{"award-number":["WKZX2024CX102217","WKZX2024CX102217","WKZX2024CX102217"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"DOI":"10.1007\/s10637-024-01485-5","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T07:37:55Z","timestamp":1736149075000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of multi-target tyrosine kinase inhibitor AL2846 combined with gemcitabine in pancreatic cancer"],"prefix":"10.1007","author":[{"given":"Rui","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaqi","family":"Xin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lila","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaohua","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Le","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Ning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuchong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongli","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Ba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"key":"1485_CR1","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/cac2.12197","volume":"41","author":"H Qiu","year":"2021","unstructured":"Qiu H, Cao S, Xu R (2021) Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. Cancer Commun 41:1037\u20131048","journal-title":"Cancer Commun"},{"key":"1485_CR2","doi-asserted-by":"publisher","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","volume":"19","author":"MA Tempero","year":"2021","unstructured":"Tempero MA, Malafa MP, Al-Hawary M et al (2021) Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 19:439\u201357","journal-title":"J Natl Compr Canc Netw"},{"key":"1485_CR3","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817\u20131825","journal-title":"N Engl J Med"},{"key":"1485_CR4","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691\u20131703","journal-title":"N Engl J Med"},{"key":"1485_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70:7\u201330","journal-title":"CA Cancer J Clin"},{"key":"1485_CR6","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1097\/SLA.0000000000002234","volume":"267","author":"VP Groot","year":"2018","unstructured":"Groot VP, Rezaee N, Wu W et al (2018) Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma. Ann Surg 267:936\u2013945","journal-title":"Ann Surg"},{"key":"1485_CR7","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1158\/2159-8290.CD-22-0876","volume":"13","author":"C Falcomat\u00e0","year":"2023","unstructured":"Falcomat\u00e0 C, B\u00e4rthel S, Schneider G, Rad R, Schmidt-Supprian M, Saur D (2023) Context-Specific Determinants of the Immunosuppressive Tumor Microenvironment in Pancreatic Cancer. Cancer Discov 13:278\u2013297","journal-title":"Cancer Discov"},{"key":"1485_CR8","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S1470-2045(21)00578-7","volume":"23","author":"PY Wen","year":"2022","unstructured":"Wen PY, Stein A, van den Bent M et al (2022) Dabrafenib plus trametinib in patients with BRAF(V600E)-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. Lancet Oncol 23:53\u201364","journal-title":"Lancet Oncol"},{"key":"1485_CR9","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","volume":"23","author":"V Subbiah","year":"2022","unstructured":"Subbiah V, Wolf J, Konda B et al (2022) Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial. Lancet Oncol 23:1261\u20131273","journal-title":"Lancet Oncol"},{"key":"1485_CR10","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"G Talia","year":"2019","unstructured":"Talia G, Pascal H, Michele R et al (2019) Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med 381:317\u2013327","journal-title":"N Engl J Med"},{"key":"1485_CR11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/bs.acr.2023.02.004","volume":"159","author":"S Khan","year":"2023","unstructured":"Khan S, Budamagunta V, Zhou D (2023) Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies. Adv Cancer Res 159:145\u2013184","journal-title":"Adv Cancer Res"},{"key":"1485_CR12","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41571-020-0377-z","volume":"17","author":"R Guo","year":"2020","unstructured":"Guo R, Luo J, Chang J, Rekhtman N, Arcila M, Drilon A (2020) MET-dependent solid tumours - molecular diagnosis and targeted therapy. Nat Rev Clin Oncol 17:569\u2013587","journal-title":"Nat Rev Clin Oncol"},{"key":"1485_CR13","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/nrclinonc.2017.40","volume":"14","author":"CA Bradley","year":"2017","unstructured":"Bradley CA, Salto-Tellez M, Laurent-Puig P et al (2017) Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges. Nat Rev Clin Oncol 14:562\u2013576","journal-title":"Nat Rev Clin Oncol"},{"key":"1485_CR14","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","volume":"186","author":"CJ Halbrook","year":"2023","unstructured":"Halbrook CJ, Lyssiotis CA, di Magliano MP, Maitra A (2023) Pancreatic cancer: Advances and challenges. Cell 186:1729\u201354","journal-title":"Cell"},{"key":"1485_CR15","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/annonc\/mds135","volume":"23","author":"A Gon\u00e7alves","year":"2012","unstructured":"Gon\u00e7alves A, Gilabert M, Fran\u00e7ois E et al (2012) BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann Oncol 23:2799\u20132805","journal-title":"Ann Oncol"},{"key":"1485_CR16","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1016\/j.ejca.2013.04.002","volume":"49","author":"P Rougier","year":"2013","unstructured":"Rougier P, Riess H, Manges R et al (2013) Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer. Eur J Cancer 49:2633\u20132642","journal-title":"Eur J Cancer"},{"key":"1485_CR17","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/cas.12674","volume":"106","author":"H Yamaue","year":"2015","unstructured":"Yamaue H, Tsunoda T, Tani M et al (2015) Randomized phase II\/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study. Cancer Sci 106:883\u2013890","journal-title":"Cancer Sci"},{"key":"1485_CR18","doi-asserted-by":"publisher","first-page":"100620","DOI":"10.1016\/j.ctarc.2022.100620","volume":"32","author":"TC Elebiyo","year":"2022","unstructured":"Elebiyo TC, Rotimi D, Evbuomwan IO et al (2022) Reassessing vascular endothelial growth factor (VEGF) in anti-angiogenic cancer therapy. Cancer Treat Res Commun 32:100620","journal-title":"Cancer Treat Res Commun"},{"key":"1485_CR19","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12943-019-1090-3","volume":"18","author":"C Zhu","year":"2019","unstructured":"Zhu C, Wei Y, Wei X (2019) AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. Mol Cancer 18:153","journal-title":"Mol Cancer"},{"key":"1485_CR20","doi-asserted-by":"publisher","first-page":"e627","DOI":"10.1038\/cddis.2013.158","volume":"4","author":"C Hage","year":"2013","unstructured":"Hage C, Rausch V, Giese N et al (2013) The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer. Cell Death Dis 4:e627","journal-title":"Cell Death Dis"},{"key":"1485_CR21","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s10637-016-0376-1","volume":"34","author":"DB Zhen","year":"2016","unstructured":"Zhen DB, Griffith KA, Ruch JM et al (2016) A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer. Invest New Drugs 34:733\u2013739","journal-title":"Invest New Drugs"},{"key":"1485_CR22","doi-asserted-by":"publisher","first-page":"7279","DOI":"10.1038\/s41388-020-01500-y","volume":"39","author":"Q He","year":"2020","unstructured":"He Q, Lin Z, Wang Z et al (2020) SIX4 promotes hepatocellular carcinoma metastasis through upregulating YAP1 and c-MET. Oncogene 39:7279\u20137295","journal-title":"Oncogene"},{"key":"1485_CR23","doi-asserted-by":"publisher","first-page":"e22316","DOI":"10.1002\/jbt.22316","volume":"33","author":"JF Yao","year":"2019","unstructured":"Yao JF, Li XJ, Yan LK et al (2019) Role of HGF\/c-Met in the treatment of colorectal cancer with liver metastasis. J Biochem Mol Toxicol 33:e22316","journal-title":"J Biochem Mol Toxicol"},{"key":"1485_CR24","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1158\/2159-8290.CD-20-1500","volume":"11","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Yang Q, Zeng X et al (2021) MET Amplification Attenuates Lung Tumor Response to Immunotherapy by Inhibiting STING. Cancer Discov 11:2726\u20132737","journal-title":"Cancer Discov"},{"key":"1485_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eururo.2021.10.025","volume":"81","author":"AK Lindner","year":"2022","unstructured":"Lindner AK, Pichler M, Thurnher M, Pichler R (2022) Targeting c-Met to Improve Immune Checkpoint Inhibition in Metastatic Renal Cell Carcinoma. Eur Urol 81:1\u20132","journal-title":"Eur Urol"},{"key":"1485_CR26","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s13046-021-02055-w","volume":"40","author":"E Li","year":"2021","unstructured":"Li E, Huang X, Zhang G, Liang T (2021) Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy. J Exp Clin Cancer Res 40:279","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-024-01485-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-024-01485-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-024-01485-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T20:03:07Z","timestamp":1736193787000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-024-01485-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":26,"alternative-id":["1485"],"URL":"https:\/\/doi.org\/10.1007\/s10637-024-01485-5","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"type":"print","value":"0167-6997"},{"type":"electronic","value":"1573-0646"}],"subject":[],"published":{"date-parts":[[2025,1,6]]},"assertion":[{"value":"21 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}